Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension.

Publication ,  Journal Article
Kopeć, G; Waligóra, M; Tyrka, A; Jonas, K; Pencina, MJ; Zdrojewski, T; Moertl, D; Stokwiszewski, J; Zagożdżon, P; Podolec, P
Published in: Sci Rep
February 15, 2017

Low-density lipoprotein cholesterol(LDL-C) is a well established metabolic marker of cardiovascular risk, however, its role in pulmonary arterial hypertension (PAH) has not been determined. Therefore we assessed whether LDL-C levels are altered in PAH patients, if they are associated with survival in this group and whether pulmonary hypertension (PH) reversal can influence LDL-C levels. Consecutive 46 PAH males and 94 females were age matched with a representative sample of 1168 males and 1245 females, respectively. Cox regression models were used to assess the association between LDL-C and mortality. The effect of PH reversal on LDL-C levels was assessed in 34 patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing invasive treatment. LDL-C was lower in both PAH (2.6 ± 0.8 mmol/l) and CTEPH (2.7 ± 0.7 mmol/l) patients when compared to controls (3.2 ± 1.1 mmol/l, p < 0.001). In PAH patients lower LDL-C significantly predicted death (HR:0.44/1 mmol/l, 95%CI:0.26-0.74, p = 0.002) after a median follow-up time of 33(21-36) months. In the CTEPH group, LDL-C increased (from 2.6[2.1-3.2] to 4.0[2.8-4.9]mmol/l, p = 0.01) in patients with PH reversal but remained unchanged in other patients (2.4[2.2-2.7] vs 2.3[2.1-2.5]mmol/l, p = 0.51). We concluded that LDL-C level is low in patients with PAH and is associated with an increased risk of death. Reversal of PH increases LDL-C levels.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Sci Rep

DOI

EISSN

2045-2322

Publication Date

February 15, 2017

Volume

7

Start / End Page

41650

Location

England

Related Subject Headings

  • Sex Factors
  • Risk Factors
  • Proportional Hazards Models
  • Prognosis
  • Middle Aged
  • Male
  • Hypertension, Pulmonary
  • Humans
  • Follow-Up Studies
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kopeć, G., Waligóra, M., Tyrka, A., Jonas, K., Pencina, M. J., Zdrojewski, T., … Podolec, P. (2017). Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension. Sci Rep, 7, 41650. https://doi.org/10.1038/srep41650
Kopeć, Grzegorz, Marcin Waligóra, Anna Tyrka, Kamil Jonas, Michael J. Pencina, Tomasz Zdrojewski, Deddo Moertl, Jakub Stokwiszewski, Paweł Zagożdżon, and Piotr Podolec. “Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension.Sci Rep 7 (February 15, 2017): 41650. https://doi.org/10.1038/srep41650.
Kopeć G, Waligóra M, Tyrka A, Jonas K, Pencina MJ, Zdrojewski T, et al. Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension. Sci Rep. 2017 Feb 15;7:41650.
Kopeć, Grzegorz, et al. “Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension.Sci Rep, vol. 7, Feb. 2017, p. 41650. Pubmed, doi:10.1038/srep41650.
Kopeć G, Waligóra M, Tyrka A, Jonas K, Pencina MJ, Zdrojewski T, Moertl D, Stokwiszewski J, Zagożdżon P, Podolec P. Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension. Sci Rep. 2017 Feb 15;7:41650.

Published In

Sci Rep

DOI

EISSN

2045-2322

Publication Date

February 15, 2017

Volume

7

Start / End Page

41650

Location

England

Related Subject Headings

  • Sex Factors
  • Risk Factors
  • Proportional Hazards Models
  • Prognosis
  • Middle Aged
  • Male
  • Hypertension, Pulmonary
  • Humans
  • Follow-Up Studies
  • Female